# To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension

Study · id `cardio:ct-nct03261375` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03261375](<https://clinicaltrials.gov/study/NCT03261375>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03261375

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

## Technical summary

Registry record NCT03261375. Randomized; double masking; primary purpose treatment. Start 2021-01-19 (actual); primary completion 2022-12-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 205 participants (enrolled count; ClinicalTrials.gov record NCT03261375, source copy `cardio:ctgov-nct03261375-2023-01-04`, retrieved 2026-10-26)
- Started: 2021-01-19 (actual) (ClinicalTrials.gov record NCT03261375, source copy `cardio:ctgov-nct03261375-2023-01-04`, retrieved 2026-10-26)
- Primary completion: 2022-12-26 (actual) (ClinicalTrials.gov record NCT03261375, source copy `cardio:ctgov-nct03261375-2023-01-04`, retrieved 2026-10-26)
- Completion: 2022-12-26 (actual) (ClinicalTrials.gov record NCT03261375, source copy `cardio:ctgov-nct03261375-2023-01-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03261375, source copy `cardio:ctgov-nct03261375-2023-01-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03261375-2023-01-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension
- Condition: Hypertension
- Intervention (Device): Renal Artery Radiofrequency Ablation System (Generator and Catheter )
- Intervention (Drug): Antihypertensive Agents
- Intervention (Device): Sham Procedure
- Lead sponsor: Shanghai Golden Leaf MedTec Co. Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 0e4954e488a3432947524f77039710fad227a85dfc20c4050f94dea3f9da9ee6
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
